The Hatch-Waxman Act and Indian pharmaceutical firms: an analysis

Arvind Sahay and Gordhan K. Saini


In the USA, the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act or HWA) was designed to provide cheaper drugs to consumers while leaving intact a financial incentive for research and development for pharmaceutical firms. The HWA permits non-brand-name generics to market their molecules subsequent to patent expiry; however, recent judgments on ‘authorized generics’ have tilted the scale towards large pharma brand-name firms by decreasing the ‘playing space’ available to the generic manufacturer. On the other hand, recent rulings in the USA have the potential to help Indian pharmaceutical firms ...

Get Prospects of Regional Economic Cooperation in South Asia now with the O’Reilly learning platform.

O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.